| scholarly article | Q13442814 |
| P50 | author | Pierre Martineau | Q45736274 |
| Marc Ychou | Q57036797 | ||
| P2093 | author name string | Yves Pommier | |
| George L Scheffer | |||
| Bernard Pau | |||
| Isabelle Gourdier | |||
| Laurent Candeil | |||
| Maguy Del Rio | |||
| Virginie Copois | |||
| Frederic Bibeau | |||
| Qasim A Khan | |||
| Beatrice Orsetti | |||
| Delphine Peyron | |||
| Nadia Vezzio | |||
| P4510 | describes a project that uses | HCT116-SN50 | Q54882059 |
| HCT116-SN6 | Q54882061 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colon cancer | Q18555025 |
| cell line | Q21014462 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 848-854 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases | |
| P478 | volume | 109 |
| Q38767018 | A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development |
| Q36629578 | A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. |
| Q88766065 | ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia |
| Q35171274 | ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors |
| Q43206841 | ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer |
| Q37287637 | ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan |
| Q35848835 | ABCG2 expression, function, and promoter methylation in human multiple myeloma |
| Q35190691 | ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. |
| Q94569882 | ABCG2 transports anticancer drugs via a closed-to-open switch |
| Q37563366 | ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics |
| Q35067898 | Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo |
| Q37958162 | Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. |
| Q48384749 | CD44 as a drug delivery target in human cancers: where are we now? |
| Q55109900 | Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells. |
| Q37087781 | Cell-selective biological activity of rhodium metalloinsertors correlates with subcellular localization |
| Q52678451 | Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5. |
| Q35946876 | Contribution of tumoral and host solute carriers to clinical drug response |
| Q35012940 | Deciphering cellular states of innate tumor drug responses. |
| Q38901400 | Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance |
| Q38384387 | Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. |
| Q35595044 | FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance |
| Q38743209 | FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. |
| Q33565717 | Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells |
| Q40420590 | Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy |
| Q38003156 | Human ABCG2: structure, function, and its role in multidrug resistance. |
| Q35609161 | IT-141, a Polymer Micelle Encapsulating SN-38, Induces Tumor Regression in Multiple Colorectal Cancer Models |
| Q41660826 | Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review. |
| Q37811967 | In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2) |
| Q28287024 | Irinotecan pharmacogenomics |
| Q41872813 | Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo |
| Q39645902 | Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity |
| Q46001481 | MALDI Mass Spectrometry Imaging for Evaluation of Therapeutics in Colorectal Tumor Organoids. |
| Q35902206 | Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines |
| Q97568146 | Molecular evolution of the ATP-binding cassette subfamily G member 2 gene subfamily and its paralogs in birds |
| Q36788481 | Molecular markers of chemotherapeutic response and toxicity in colorectal cancer |
| Q39534943 | New Topoisomerase I mutations are associated with resistance to camptothecin |
| Q35919726 | Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. |
| Q37564553 | Oligomerization of human ATP-binding cassette transporters and its potential significance in human disease |
| Q57211312 | Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 and |
| Q34233172 | Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells |
| Q36556926 | Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells |
| Q39614141 | Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro |
| Q36326214 | Pharmacogenetics of colorectal cancer |
| Q35911147 | Pharmacogenetics of irinotecan toxicity |
| Q34008793 | Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years |
| Q38759264 | Photodynamic therapy with 5-aminolaevulinic acid and DNA damage: unravelling roles of p53 and ABCG2. |
| Q48226662 | Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer. |
| Q33728760 | Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. |
| Q36838947 | Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection |
| Q91666045 | Radiogenomics-based cancer prognosis in colorectal cancer |
| Q40303807 | Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer |
| Q36250753 | Role of the breast cancer resistance protein (ABCG2) in drug transport |
| Q49472811 | SN38-PEG-PLGA-verapamil nanoparticles inhibit proliferation and downregulate drug transporter ABCG2 gene expression in colorectal cancer cells. |
| Q43288450 | Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression |
| Q38540360 | Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance |
| Q30439828 | Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein |
| Q35832549 | Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. |
| Q38710502 | Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo |
| Q36935258 | The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro |
| Q35793641 | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. |
| Q37923365 | Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer |
| Q90999171 | Uremic serum residue decreases SN-38 sensitivity through suppression of organic anion transporter polypeptide 2B1 in LS-180 colon cancer cells |
| Q37610090 | mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2. |
Search more.